Separately, NICE has also recommended dapagliflozin with insulin (August 2019) as an option for treating type 1 diabetes in adults with a BMI of at least 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, only if certain criteria are met.